A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator's Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

Clinical Trial Grant

Duke Scholars

Principal Investigator Angeles Alvarez Secord Obstetrics and Gynecology, Gynecologic Oncology

Awarded By

Genmab A/S

Start Date

January 12, 2026

End Date

January 8, 2031

Awarded By

Genmab A/S

Start Date

January 12, 2026

End Date

January 8, 2031